1McCormack PL, Wagstaff AJ. Lacidipine : a review of its use in the management of hypertension [ J ]. Drugs, 2003,63 (21) : 2327- 2356.
2Cominacini L, Fratta Pasini A, Garhin U, et al. Antioxidant activity of different dihydropytldines [ J ]. Biochem Biophys Res Commun, 2003,302 (4) :679-684.
3Taddei S, Virdis A, Ghiadoni L, et al. Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients [ J ]. Hypertension, 1997,30(6) : 1606-1612.
4Zanchetti A, Bond MG, Hennig M, et al. Absolute and relative changes in carotid intima-media thickness and atherosclerotic plaques during long-term antihypertensive treatment: further results of the European Lacidipine Study on Atheresclerosis (ELSA) [ J]. J Hypertens, 2004,22(6) : 1201-1212.
5Sobal G, Menzel EJ, Sinzinger H, et al. Calcium antagonists as inhibitors of in vitro low-density lipoprotein oxidation and glyeation [ J ]. Biochem Pharmacol, 2001,61 ( 3 ) : 373-379.
6Berkels R, Breitenbach T, Bartels H, et al. Different antioxidative potencies of dihydropyridine calcium channel modulators in various models [ J ]. Vasc Pharmacol, 2005,42 (4) : 145-152.
同被引文献6
1Murata T,Takahashi T,Omori M,et al. Association of abnor real diurnal blood pressure,variation with the development of silent cerebral infarction in patients with late- life- onset de- pression[J]. Gen Hosp Psychiatry,2003,25(4) :298 - 300.
